CY1119107T1 - Δυνητικα αντιγραφικος κυτομεγαλοϊος ως εμβολιο για cmv - Google Patents
Δυνητικα αντιγραφικος κυτομεγαλοϊος ως εμβολιο για cmvInfo
- Publication number
- CY1119107T1 CY1119107T1 CY20171100780T CY171100780T CY1119107T1 CY 1119107 T1 CY1119107 T1 CY 1119107T1 CY 20171100780 T CY20171100780 T CY 20171100780T CY 171100780 T CY171100780 T CY 171100780T CY 1119107 T1 CY1119107 T1 CY 1119107T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cmv
- present
- infection
- methods
- relates
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 241000701022 Cytomegalovirus Species 0.000 abstract 7
- 230000002950 deficient Effects 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007420 reactivation Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση αφορά σε μεθόδους διέγερσης ανοσοαπόκρισης σε κυτομεγαλοϊό (CMV) χρησιμοποιώντας γενετικώς τροποποιημένο CMV που είναι δυνητικά ελαττωματικός αντιγραφής. Οι μέθοδοι της εφεύρεσης μπορεί να χρησιμοποιηθούν για να θεραπεύεται ή/και να αποτρέπεται πρωτογενής CMV μόλυνση, μόλυνση λόγω επανενεργοποίησης ενός λανθάνοντος CMV και υπερ-μόλυνση ενός διαφορετικού στελέχους του CMV που είχε προηγουμένως αντιμετωπιστεί. Η παρούσα εφεύρεση επίσης αφορά σε ελαττωματικό αντιγραφής CMV που έχει ανασυνδυαστικώς μεταβληθεί για να επιτρέπει εξωτερικό έλεγχο ιικής αντιγραφής. Συνθέσεις που περιλαμβάνουν τον ελαττωματικό αντιγραφής CMV επίσης αντιμετωπίζονται με την παρούσα εφεύρεση.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161532667P | 2011-09-09 | 2011-09-09 | |
PCT/US2012/053599 WO2013036465A2 (en) | 2011-09-09 | 2012-09-04 | A conditional replicating cytomegalovirus as a vaccine for cmv |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119107T1 true CY1119107T1 (el) | 2018-02-14 |
Family
ID=47832753
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100780T CY1119107T1 (el) | 2011-09-09 | 2017-07-20 | Δυνητικα αντιγραφικος κυτομεγαλοϊος ως εμβολιο για cmv |
CY20191100836T CY1121863T1 (el) | 2011-09-09 | 2019-08-06 | Δυνητικα αντιγραφικος κυτομεγαλοϊος ως εμβολιο για cmv |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100836T CY1121863T1 (el) | 2011-09-09 | 2019-08-06 | Δυνητικα αντιγραφικος κυτομεγαλοϊος ως εμβολιο για cmv |
Country Status (33)
Country | Link |
---|---|
US (1) | US9546355B2 (el) |
EP (3) | EP3572096A1 (el) |
JP (1) | JP5926804B2 (el) |
KR (1) | KR101668163B1 (el) |
CN (1) | CN103889462B (el) |
AR (1) | AR087772A1 (el) |
AU (1) | AU2012304783B2 (el) |
BR (1) | BR112014005404A8 (el) |
CA (1) | CA2846870C (el) |
CL (1) | CL2014000541A1 (el) |
CY (2) | CY1119107T1 (el) |
DK (2) | DK3251700T3 (el) |
ES (2) | ES2737852T3 (el) |
HR (2) | HRP20171120T1 (el) |
HU (2) | HUE045115T2 (el) |
IL (1) | IL231272B (el) |
IN (1) | IN2014CN01809A (el) |
LT (2) | LT3251700T (el) |
ME (2) | ME03488B (el) |
MX (1) | MX353037B (el) |
NZ (1) | NZ622156A (el) |
PE (1) | PE20141525A1 (el) |
PL (2) | PL3251700T3 (el) |
PT (2) | PT3251700T (el) |
RS (2) | RS58891B1 (el) |
RU (2) | RU2611198C2 (el) |
SG (1) | SG11201400419YA (el) |
SI (2) | SI2753364T1 (el) |
TR (1) | TR201910644T4 (el) |
TW (1) | TWI570240B (el) |
UA (1) | UA114896C2 (el) |
WO (1) | WO2013036465A2 (el) |
ZA (1) | ZA201401708B (el) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013355368A1 (en) * | 2012-12-04 | 2015-05-28 | Merck Sharp & Dohme Corp. | Conditional replicating viral vectors |
BR112015030892A2 (pt) * | 2013-06-10 | 2017-08-29 | Merck Sharp & Dohme | Proteína de ligação ao antígeno, anticorpo monoclonal, ácido nucleico recombinante, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma proteína de ligação ao antígeno ou anticorpo humanizado, e, método para produzir uma proteína de ligação ao antígeno |
EP3169787A1 (en) | 2014-07-16 | 2017-05-24 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
EP3048114A1 (en) * | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
MA46316A (fr) | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
KR20200083540A (ko) * | 2017-11-01 | 2020-07-08 | 머크 샤프 앤드 돔 코포레이션 | 시토메갈로바이러스의 안정한 제형 |
EP3784276A4 (en) * | 2018-04-24 | 2022-03-16 | Merck Sharp & Dohme Corp. | SCALABLE CHROMATOGRAPHY METHOD FOR THE PURIFICATION OF HUMAN CYTOMEGALOVIRUS |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
WO2020142304A1 (en) | 2019-01-03 | 2020-07-09 | Merck Sharp & Dohme Corp. | Supplemented serum-containing culture medium for enhanced arpe-19 growth and human cytomegalovirus vaccine production |
WO2021008840A1 (en) * | 2019-07-12 | 2021-01-21 | Københavns Universitet | Fusion toxin proteins for treatment of diseases related to cmv infections |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CN112481222B (zh) * | 2020-11-30 | 2024-01-02 | 中国医学科学院医学生物学研究所 | 一种条件复制型重组单纯疱疹病毒、疫苗及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1150712T1 (sl) * | 1999-02-05 | 2009-02-28 | Merck & Co Inc | Pripravek cepiva proti humanem papiloma virusu |
CA2756797C (en) | 2002-12-23 | 2015-05-05 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
US20060110406A1 (en) * | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
WO2004076645A2 (en) * | 2003-02-27 | 2004-09-10 | University Of Massachusetts | Compositions and methods for cytomegalovirus treatment |
CN101203529A (zh) * | 2005-02-18 | 2008-06-18 | 诺华疫苗和诊断公司 | 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸 |
EP3031469B1 (en) * | 2006-06-07 | 2023-08-23 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
US8173792B2 (en) * | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
US9439960B2 (en) | 2007-10-10 | 2016-09-13 | The Trustees Of Princeton University | Cytomegalovirus vaccines and methods of production |
US8530636B2 (en) * | 2008-05-07 | 2013-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells in vivo using synthetic small molecules |
-
2012
- 2012-09-03 TW TW101132064A patent/TWI570240B/zh active
- 2012-09-04 SI SI201231003T patent/SI2753364T1/sl unknown
- 2012-09-04 TR TR2019/10644T patent/TR201910644T4/tr unknown
- 2012-09-04 RS RS20190753A patent/RS58891B1/sr unknown
- 2012-09-04 DK DK17171651.7T patent/DK3251700T3/da active
- 2012-09-04 CN CN201280053360.7A patent/CN103889462B/zh active Active
- 2012-09-04 KR KR1020147008959A patent/KR101668163B1/ko active IP Right Grant
- 2012-09-04 JP JP2014529788A patent/JP5926804B2/ja active Active
- 2012-09-04 RS RS20170715A patent/RS56261B1/sr unknown
- 2012-09-04 ES ES17171651T patent/ES2737852T3/es active Active
- 2012-09-04 NZ NZ622156A patent/NZ622156A/en unknown
- 2012-09-04 ME MEP-2019-176A patent/ME03488B/me unknown
- 2012-09-04 HU HUE17171651A patent/HUE045115T2/hu unknown
- 2012-09-04 AR ARP120103253A patent/AR087772A1/es active IP Right Grant
- 2012-09-04 PT PT17171651T patent/PT3251700T/pt unknown
- 2012-09-04 LT LTEP17171651.7T patent/LT3251700T/lt unknown
- 2012-09-04 EP EP19175776.4A patent/EP3572096A1/en active Pending
- 2012-09-04 UA UAA201403638A patent/UA114896C2/uk unknown
- 2012-09-04 MX MX2014002815A patent/MX353037B/es active IP Right Grant
- 2012-09-04 AU AU2012304783A patent/AU2012304783B2/en active Active
- 2012-09-04 ME MEP-2017-157A patent/ME02831B/me unknown
- 2012-09-04 WO PCT/US2012/053599 patent/WO2013036465A2/en active Application Filing
- 2012-09-04 US US14/343,637 patent/US9546355B2/en active Active
- 2012-09-04 BR BR112014005404A patent/BR112014005404A8/pt not_active Application Discontinuation
- 2012-09-04 EP EP17171651.7A patent/EP3251700B1/en active Active
- 2012-09-04 CA CA2846870A patent/CA2846870C/en active Active
- 2012-09-04 DK DK12830346.8T patent/DK2753364T3/en active
- 2012-09-04 PT PT128303468T patent/PT2753364T/pt unknown
- 2012-09-04 SG SG11201400419YA patent/SG11201400419YA/en unknown
- 2012-09-04 IN IN1809CHN2014 patent/IN2014CN01809A/en unknown
- 2012-09-04 RU RU2014113921A patent/RU2611198C2/ru active
- 2012-09-04 PE PE2014000323A patent/PE20141525A1/es active IP Right Grant
- 2012-09-04 PL PL17171651T patent/PL3251700T3/pl unknown
- 2012-09-04 PL PL12830346T patent/PL2753364T3/pl unknown
- 2012-09-04 SI SI201231634T patent/SI3251700T1/sl unknown
- 2012-09-04 ES ES12830346.8T patent/ES2633190T3/es active Active
- 2012-09-04 RU RU2017102888A patent/RU2670012C1/ru active
- 2012-09-04 HU HUE12830346A patent/HUE035322T2/en unknown
- 2012-09-04 LT LTEP12830346.8T patent/LT2753364T/lt unknown
- 2012-09-04 EP EP12830346.8A patent/EP2753364B1/en active Active
-
2014
- 2014-03-02 IL IL231272A patent/IL231272B/en active IP Right Grant
- 2014-03-06 CL CL2014000541A patent/CL2014000541A1/es unknown
- 2014-03-07 ZA ZA2014/01708A patent/ZA201401708B/en unknown
-
2017
- 2017-07-20 HR HRP20171120TT patent/HRP20171120T1/hr unknown
- 2017-07-20 CY CY20171100780T patent/CY1119107T1/el unknown
-
2019
- 2019-06-18 HR HRP20191111TT patent/HRP20191111T1/hr unknown
- 2019-08-06 CY CY20191100836T patent/CY1121863T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119107T1 (el) | Δυνητικα αντιγραφικος κυτομεγαλοϊος ως εμβολιο για cmv | |
CY1123563T1 (el) | Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων | |
CY1119445T1 (el) | Αντισωματα εναντι του ανθρωπινου gdf8 | |
CY1122909T1 (el) | Μεθοδοι αντιμετωπισης της ηωσινοφιλικης οισοφαγιτιδας με χορηγηση αναστολεα του ιl-4r | |
CY1124959T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
CY1121591T1 (el) | Ογκολυτικος ιος απλου ερπητα και θεραπευτικες χρησεις αυτου | |
CY1123339T1 (el) | Τρι-τμηματικοι αρεναϊοι ως φορεις εμβολιου | |
CY1123774T1 (el) | Στελεχη shigella me υπερφυσαλιδωση | |
EP4219696A3 (en) | Oncolytic virus strain | |
CY1120987T1 (el) | Cmv γλυκοπρωτεϊνες και ανασυνδυασμενοι φορεις | |
CY1125387T1 (el) | Αντιγονα, διαβιβαστες, συνθεσεις του ιου της ανθρωπινης ανοσοανεπαρκειας, και μεθοδοι χρησης τους | |
BR112019001737A2 (pt) | expressão de pten-long com vírus oncolíticos | |
EA201790533A1 (ru) | Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для модулирования экспрессии генов | |
CY1121972T1 (el) | Mono- ή διυποκατεστημενα ινδολια ως αναστολεις του αναδιπλασιασμου του ιου του δαγκειου πυρετου | |
BR112013009164A2 (pt) | capsídeo de norovírus e proteína vp6 de rotavírus para uso como vacina combinada. | |
CY1116775T1 (el) | Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης | |
CY1120607T1 (el) | Παραγωγα ισοϊνδολινης για χρηση στη θεραπεια μιας ιικης μολυνσης | |
EA201790327A1 (ru) | Соединения замещенного пиперидина | |
BR112016026721A2 (pt) | vacinas com base em vesículas do tipo vírus (vlvs) para prevenir ou tratar infecção por vírus da hepatite b (hbv) crônica | |
ME01140B (me) | Virus goveđe virusne dijareje s modifikovanim erns proteinom | |
BR112017004202A2 (pt) | composições para intensificar respostas imunes e seus usos | |
PH12016501968A1 (en) | Novel macrocyclic compounds | |
CY1124707T1 (el) | Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων) | |
EA201691443A1 (ru) | Накожное восстановление иммунобаланса | |
EA201790517A1 (ru) | Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции |